These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28533923)

  • 1. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
    Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
    World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extra burden of infliximab infusions in inflammatory bowel disease.
    Buisson A; Seigne AL; Dʼhuart MC; Bigard MA; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2013 Oct; 19(11):2464-7. PubMed ID: 23942563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
    Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.
    O'Connell DM; Nachreiner J; Shu X; Terry E; Imburgia T; Vanderloo J; Lasarev MR; Bogenschutz M
    J Pediatr Gastroenterol Nutr; 2022 May; 74(5):605-609. PubMed ID: 35149648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol.
    Ong WC; Lim MS; Chan E; Lim TCT; Lim TG; Chan W
    JGH Open; 2022 Jul; 6(7):470-476. PubMed ID: 35822121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn's disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.
    Martínez-Lozano H; Miranda-Bautista J; González-Lama Y; Carpio D; Barreiro-de Acosta M; Pérez-Calle JL; Relea Pérez L; Villa K; Matallana V; Calvo M; Vera MI; Pérez Galindo P; Mora-Cuadrado N; López-Serrano P; Marín-Jiménez I; Menchén L
    Rev Esp Enferm Dig; 2021 Mar; 113(3):170-178. PubMed ID: 33213166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.
    Poullenot F; Ollivier J; Rivière P; Sauvaget L; Berroneau A; Djabarouti S; Xuereb F; Zerbib F; Breilh D; Laharie D
    Dig Liver Dis; 2020 Apr; 52(4):408-413. PubMed ID: 31874834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.
    Teich N; Bläker M; Holtkamp-Endemann F; Jörgensen E; Stallmach A; Hohenberger S
    Inflamm Intest Dis; 2021 Feb; 6(1):48-60. PubMed ID: 33850839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
    Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
    Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.